Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

A Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease

To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease.

Inclusion Criteria:

• Diagnosis of probable Alzheimer's Disease with Mini-Mental State Examination (MMSE) score of 16-26 (except Germany: 21-26)
• Brain MRI consistent with Alzheimer Disease
• Concurent use of Chloniesterase inhibitor or memantine allowed if stable
• Other inclusion criteria apply

Exclusion Criteria:

• Significant Neurological Disease other than Alzheimer's disease
• Major psychiatric disorder
• Contraindication to undergo brain MRI
• Clinically significant systemic illness
• Other exclusion criteria apply